IRB Ready

Full Board IRB Review

Full board review is required when research involves greater than minimal risk, vulnerable populations, or significant deception. The convened IRB reviews the protocol at a scheduled meeting.

Typical approval time: 6–10 weeks

Full board review is the default level of IRB oversight under the Common Rule. If your research does not qualify for exempt or expedited review, the convened board — a quorum of IRB members meeting on a fixed schedule — evaluates your protocol under 45 CFR 46.108 and 45 CFR 46.111.

Full board is not a punishment. It exists because some research carries real risks that warrant discussion among scientists, ethicists, and community members together.

When full board review is required

Your study almost certainly requires full board review if any of the following apply:

  • Research involves greater than minimal risk (physical, psychological, social, legal, or economic harm beyond daily life)
  • Interventions carry a realistic chance of distress, injury, or adverse event
  • Research involves prisoners (45 CFR 46 Subpart C)
  • Research with pregnant women, fetuses, or neonates that does not qualify for expedited review (45 CFR 46 Subpart B)
  • Research with children that involves greater than minimal risk (45 CFR 46 Subpart D)
  • Research involving deception that could reasonably affect a participant's willingness to participate
  • FDA-regulated drug or device studies requiring an IND or IDE
  • Research with populations whose capacity to consent is impaired

Read our special populations guide for detailed regulatory requirements when enrolling vulnerable groups.

Typical timeline

Weeks 1–2
Administrative pre-review
IRB staff screen for completeness and assign the protocol to an upcoming meeting agenda. Most boards meet monthly with a submission deadline two to three weeks before the meeting.
Weeks 2–4
Primary and secondary reviewer assignment
Two or more members read the protocol in depth and prepare written critiques that structure the meeting discussion.
Week 4–5
Convened meeting
The board discusses the protocol with a quorum (majority plus at least one non-scientific member). Possible outcomes: approved, approved with modifications, deferred, disapproved.
Weeks 5–9
Revision and response
Most first-time submissions receive "approved with modifications required for approval" or "deferred." You prepare a point-by-point response; minor revisions can be approved by the chair, substantive ones return to the full board.
Weeks 8–10
Final approval
Approval letter issued. Approval periods are typically one year.

Plan on 6–10 weeks from submission to final approval for a well-prepared first-time submission. Protocols with extensive revisions or deferred decisions can extend beyond this range.

The meeting process

At a convened meeting, the IRB must have a quorum including at least one non-scientist (45 CFR 46.108(b)). Your protocol is presented by the primary reviewer, discussed by members, and voted on. You generally do not attend unless invited to answer questions.

To approve research, the IRB must affirmatively find all criteria at 45 CFR 46.111 are met:

What reviewers must find

  • Risks to subjects are minimized
  • Risks are reasonable in relation to anticipated benefits
  • Selection of subjects is equitable
  • Informed consent will be sought from each prospective subject or legally authorized representative
  • Informed consent will be appropriately documented
  • Adequate provisions exist for monitoring data to ensure subject safety
  • Adequate provisions exist to protect privacy and maintain confidentiality
  • Additional safeguards exist when vulnerable populations are involved

What reviewers look for

  • Risk minimization logic. Can you articulate why each risky procedure is necessary, and what alternatives you considered?
  • A defensible risk/benefit analysis. Benefits to subjects and society must be named clearly, not assumed.
  • A readable consent form. Plain language, 8th-grade reading level, all required elements under 45 CFR 46.116.
  • A concrete data safety plan. Who has access, where data are stored, how adverse events will be detected and reported.
  • An equitable recruitment plan. Inclusion and exclusion criteria that match the science and do not arbitrarily exclude protected groups.
  • Qualified personnel. CITI training current, appropriate clinical credentials for any invasive procedures.

Preparation tips

Write for three readers

Your protocol will be read by a methodologist, a clinician or subject-matter expert, and a non-scientist community member. Define jargon, justify design choices, and explain why the study matters to someone outside your field.

  • Meet the deadline ahead of the deadline. Submit at least one week before the official cutoff to allow pre-review back-and-forth.
  • Pre-empt the common critiques. Address risk mitigation, data security, and participant withdrawal rights explicitly rather than hoping reviewers miss them.
  • Align consent and protocol. Word-for-word inconsistencies between the two documents are the single most common revision request.
  • Build in a safety monitoring plan even for low-probability adverse events.
  • Draft a one-page protocol summary that a non-scientist member can absorb in five minutes.
  • Expect revisions. Few full-board protocols are approved without modification on first pass. A detailed, respectful response letter speeds re-review.

Approval is not perpetual

Full-board studies generally require continuing review at intervals determined by the IRB but no less than annually (45 CFR 46.109(e)). See the amendments and continuing review guide for post-approval obligations.

If you are early in the process, start with our protocol writing walkthrough, then move to consent forms and data management before you submit.